Form 4 for SNDX Syndax Pharmaceuticals Inc
Accepted 2025-09-08 00:00:00 ET · period of report 2025-09-08 · accession 0000950170-25-113659 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2025-09-08 | 2025-09-08 | SNDX | Metzger Michael A | CEO, Dir | S - Sale+OE | $16.41 | -157.3K | 298.7K | -34% | -$2.58M |
| DT | 2025-09-08 | 2025-09-08 | SNDX | Metzger Michael A | CEO, Dir | M - OptEx | $10.90 | +157.3K | 456.0K | +53% | +$1.71M |
| DT | 2025-09-08 | 2025-09-08 | SNDX | Metzger Michael A | CEO, Dir | M - OptEx | $0.00 | +157.3K | 0 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-08 | S | D | 157,307 | $16.41 | 298,661 | D | — | — | (F2) The sale prices ranged from $16.21 to $17.06. |
| 2 | Common | Common Stock | 2025-09-08 | M | A | 157,307 | $10.90 | 455,968 | D | — | — | |
| 3 | Derivative | Stock options (Right to buy) | 2025-09-08 | M | A | 157,307 | $0.00 | 0 | D | $10.90 · — to 2025-09-09 | 157,307 Common Stock | (F3) This option is fully vested. |